Scalzulli E., Grammatico S., Vozella F., Petrucci M.T. 2018. Proteasome inhibitors for the treatment of multiple myeloma. Expert Opin. Pharmacother. 19 (4), 375‒386. https://doi.org/10.1080/14656566.2018.1441287

Article  CAS  PubMed  Google Scholar 

Du B., Jiang Q.L., Cleveland J., Liu B.R., Zhang D. 2016. Targeting Toll-like receptors against cancer. J. Cancer Metastasis Treat. 2 (12), 463‒470. https://doi.org/10.20517/2394-4722.2016.62

Article  CAS  Google Scholar 

Zhang C., Wu S., Chen B. 2023. A novel prognostic model based on pyroptosis-related genes for multiple myeloma. BMC Med. Genomics. 16 (1), 32. https://doi.org/10.1186/s12920-023-01455-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Touzeau C., Maciag P., Amiot M., Moreau P. 2018. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 32 (9), 1899‒1907. https://doi.org/10.1038/s41375-018-0223-9

Article  CAS  PubMed  Google Scholar 

Manasanch E.E., Orlowski R.Z. 2017. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 14 (7), 417‒433. https://doi.org/10.1038/nrclinonc.2016.206

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thakur K.K., Bolshette N.B., Trandafir C., Jamdade V.S., Istrate A., Gogoi R., Cucuianu A. 2015. Role of toll-like receptors in multiple myeloma and recent advances. Exp. Hematol. 43 (3), 158‒167. https://doi.org/10.1016/j.exphem.2014.11.003

Article  CAS  PubMed  Google Scholar 

Elbezanti W.O., Challagundla K.B., Jonnalagadda S.C., Budak-Alpdogan T., Pandey M.K. 2023. Past, present, and a glance into the future of multiple myeloma treatment. Pharmaceuticals. 16 (3), 415. https://doi.org/10.3390/ph16030415

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gulla A., Anderson K.C. 2020. Multiple myeloma: The (r)evolution of current therapy and a glance into the future. Haematologica. 105 (10), 2358‒2367. https://doi.org/10.3324/haematol.2020.247015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho M., Xiao A., Yi D., Zanwar S., Bianchi G. 2022. Treating multiple myeloma in the context of the bone marrow microenvironment. Curr. Oncol. 29 (11), 8975‒9005. https://doi.org/10.3390/curroncol29110705

Article  PubMed  PubMed Central  Google Scholar 

Anwer F., Gee K.M., Iftikhar A., Baig M., Russ A.D., Saeed S., Zar M.A., Razzaq F., Carew J., Nawrocki S., Al-Kateb H., Cavalcante Parr N.N., McBride A., Valent J., Samaras C. 2019. Future of personalized therapy targeting aberrant signaling pathways in multiple myeloma. Clin. Lymphoma Myeloma Leuk. 19 (7), 397‒405. https://doi.org/10.1016/j.clml.2019.03.017

Article  PubMed  PubMed Central  Google Scholar 

Swamydas M., Murphy E.V., Ignatz-Hoover J.J., Malek E., Driscoll J.J. 2022. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J. Hematol. Oncol. 15 (1), 17. https://doi.org/10.1186/s13045-022-01234-2

Article  PubMed  PubMed Central  Google Scholar 

Monlish D.A., Bhatt S.T., Schuettpelz L.G. 2016. The role of Toll-like receptors in hematopoietic malignancies. Front. Immunol. 7, 390. https://doi.org/10.3389/fimmu.2016.00390

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnstone M., Vinaixa D., Turi M., Morelli E., Anderson K.C., Gulla A. 2022. Promises and challenges of immunogenic chemotherapy in multiple myeloma. Cells. 11 (16), 2519. https://doi.org/10.3390/cells11162519

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdi J., Engels F., Garssen J., Redegeld F. 2011. The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Crit. Rev. Oncol. Hematol. 80 (2), 225‒240. https://doi.org/10.1016/j.critrevonc.2010.12.001

Article  PubMed  Google Scholar 

Liu Z., Yang C., Liu X., Xu X., Zhao X., Fu R. 2023. Therapeutic strategies to enhance immune response induced by multiple myeloma cells. Front. Immunol. 14, 1169541. https://doi.org/10.3389/fimmu.2023.1169541

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiron D., Bekeredjian-Ding I., Pellat-Deceunynck C., Bataille R., Jego G. 2008. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood. 112 (6), 2205‒2213. https://doi.org/10.1182/blood-2008-02-140673

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akesolo O., Buey B., Beltrán-Visiedo M., Giraldos D., Marzo I., Latorre E. 2022. Toll-like receptors: New targets for multiple myeloma treatment? Biochem. Pharmacol. 199. 114992. https://doi.org/10.1016/j.bcp.2022.114992

Article  CAS  PubMed  Google Scholar 

Cho H.Y., Lee S.W. 2014. TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells. Cell Immunol. 289 (1‒2), 27‒35. https://doi.org/10.1016/j.cellimm.2014.03.003

Article  CAS  PubMed  Google Scholar 

Ray A., Tian Z., Das D.S., Coffman R.L., Richardson P., Chauhan D., Anderson K.C. 2014. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia. 28 (8), 1716‒1724. https://doi.org/10.1038/leu.2014.46

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salaun B., Coste I., Rissoan M.C., Lebecque S.J., Renno T. 2006. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176 (8), 4894‒4901. https://doi.org/10.4049/jimmunol.176.8.4894

Article  CAS  PubMed  Google Scholar 

Abdi J., Mutis T., Garssen J., Redegeld FA. 2014. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis. PLoS One. 9 (5), e96608. https://doi.org/10.1371/journal.pone.0096608

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdi J., Mutis T., Garssen J., Redegeld F. 2013. Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells. Blood Cancer J. 3 (5), e119. https://doi.org/10.1038/bcj.2013.17

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niewerth D., Jansen G., Assaraf Y.G., Zweegman S., Kaspers G.J.L., Cloos J. 2015. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist. Updat. 18, 18‒35. https://doi.org/10.1016/j.drup.2014.12.001

Article  PubMed  Google Scholar 

Song Y., Li S., Ray, A., Das D.S., Qi J., Samur M.K., Tai Y.-T., Munshi N., Carrasco R.D., Chauhan D., Anderson K.C. 2017. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Physiol. Behav. 36 (40), 5631–5638. https://doi.org/10.1038/onc.2017.172

Article  CAS  Google Scholar 

Chauhan D., Tian Z., Nicholson B., Kumar K.G., Zhou B., Carrasco R., McDermott J.L., Leach C.A., Fulcinniti M., Kodrasov M.P., Weinstock J., King-sbury W.D., Hideshima T., Shah P.K., Minvielle S., Altun M., Kessler B.M., Orlowski R., Richardson P., Munshi N., Anderson K.C. 2012. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 22 (3), 345‒358. https://doi.org/10.1016/j.ccr.2012.08.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yue X.Y., Chen Q., He J.S. 2020. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 20 (1), 524. https://doi.org/10.1186/s12935-020-01614-z

Article  CAS